MaxCyte Inc. (MXCT)
NASDAQ: MXCT
· Real-Time Price · USD
1.53
0.00 (0.00%)
At close: Sep 26, 2025, 10:59 AM
0.00% (1D)
| Bid | 1.53 |
| Market Cap | 163.64M |
| Revenue (ttm) | 35.75M |
| Net Income (ttm) | -44.77M |
| EPS (ttm) | -0.42 |
| PE Ratio (ttm) | -3.65 |
| Forward PE | -4.15 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 1.54 |
| Volume | 173,973 |
| Avg. Volume (20D) | 865,470.5 |
| Open | 1.52 |
| Previous Close | 1.53 |
| Day's Range | 1.51 - 1.56 |
| 52-Week Range | 1.26 - 5.20 |
| Beta | 0.29 |
| Ex-Dividend Date | n/a |
About MXCT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MXCT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MXCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsMaxCyte Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
+10.32%
MaxCyte shares are trading higher after the compan...
Unlock content with
Pro Subscription
1 month ago
-29.9%
MaxCyte shares are trading lower after the company reported worse-than-expected Q2 financial results. Additionally, William Blair downgraded the stock from Outperform to Market Perform.
1 month ago · fool.com
MaxCyte (MXCT) Q2 Revenue Drops 18%MaxCyte (MXCT) Q2 Revenue Drops 18%
2 months ago · businesswire.com
PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in JapanTOKYO--(BUSINESS WIRE)--The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHCbi"), a subsidiary of PHC Holdings Corpor...